Sermorelin-Related GRF(1–29)-NH₂: Deamidation and Backbone Rearrangement

Sermorelin-related research requires more precision than “GHRH fragment.” For the chemistry discussed here, the experimental molecule is human growth hormone-releasing factor residues 1–29 with an amidated C terminus, written GRF(1–29)-NH₂. Bongers and colleagues explicitly investigated this species alongside GRF(1–44)-NH₂ in a primary degradation study published in 1992. It supplies direct evidence about the amidated 29-residue fragment rather than requiring inference from another endocrine peptide. Primary study

A defined fragment, not a whole family

The terminal notation matters. “1–29” identifies residue boundaries; “NH₂” specifies the C-terminal amide. Results with that molecule should not silently be reassigned to a free-acid version, differently substituted analog or longer fragment. A shared relationship to growth hormone-releasing factor does not establish identical chemistry.

The historical parent structure is independently grounded in primary research. Ling and colleagues isolated human hypothalamic GRF and characterized a 44-residue amidated peptide using sequence determination and chromatographic comparison with synthetic material. This establishes the parent sequence context; it does not make every shorter derivative equivalent. Parent characterization

Two vulnerable positions, several products

Bongers and colleagues investigated degradation in aqueous solutions and isolated products associated with Asp3 and Asn8. For GRF(1–29)-NH₂ these included a cleavage product beginning at residue 4, an Asp3 isomerization product and Asn8 deamidation products. The study distinguishes chain cleavage from changes leaving the chain largely intact. Degradation products

A sample need not break into conspicuously smaller fragments to change chemically. Rearrangement at one residue can generate a different species while preserving most of the original structure. Summarizing all those outcomes as “breakdown” hides the analytical distinctions that make the study useful.

Acidic cleavage and Asp3 isomerization

Below approximately pH 4, cleavage at the Asp3–Ala4 bond was the major reported route. Above pH 4, isomerization of Asp3 to beta-Asp3, also called isoAsp3, predominated for that residue’s degradation. The authors related the competing outcomes to the Asp side chain’s protonation state. These observations describe experimental conditions, not recommended preparation settings. Pathway comparison

Isoaspartate formation changes connectivity, not simply the amino-acid count. A related impurity may retain overall composition while differing in how the chain passes through that residue. Expected molecular mass alone would not resolve this structural question. It remains necessary to distinguish the parent from relevant alternatives rather than assuming a matching mass answers every identity question.

Asn8 deamidation creates another branch

At pH 8.0, the researchers isolated both Asp8 and beta-Asp8 products from the amidated fragment. They reported more rapid Asn8 deamidation at pH values of at least 5, producing beta-Asp and Asp forms in approximately a 4:1 ratio, and proposed a cyclic imide intermediate. They also reported evidence for direct hydrolysis under strongly acidic conditions. Deamidation results

The ratio and interpretation belong to the experimental system. They are not a fixed impurity profile for every preparation. The broader conclusion is that one starting residue can generate more than one product, and the environment helps determine the pathway balance.

Kinetics depend on the pathway

The study described Asp-related cleavage and isomerization as first-order processes varying with pH. It distinguished these from Asn8 deamidation, which showed general base catalysis. The reported stability maximum around pH 4–5 therefore reflects competing pathways, not proof that a single reaction explains the entire profile.

A minimum in overall degradation does not mean absence of change. It identifies a relative experimental optimum across examined conditions. Nor does a solution result establish behavior in a dried preparation, another buffer or a different container. The observed system must remain attached to its rate description. Kinetic findings

Chemical change and biological activity

Isolated degradation products had substantially lower in-vitro potency than corresponding parent peptides. This connects characterized chemical change with a functional consequence in the study’s assay. It does not establish human outcomes or assign a predictable effect to an unspecified impurity mixture.

The paper supports site-specific cleavage, isomerization and deamidation in amidated GRF(1–29), with pathway balance influenced by solution environment. It supplies no universal storage period or lot-release conclusion. The sermorelin research record and COA Library concern separate material evidence.